A Tribute to Paul Greengard (1925-2019)

1st Edition, Volume 90 - March 2, 2021
Imprint: Academic Press
Editor: Stevin H. Zorn
Language: English
Hardback ISBN:
9 7 8 - 0 - 1 2 - 8 2 2 5 1 6 - 5
eBook ISBN:
9 7 8 - 0 - 1 2 - 8 2 2 5 1 7 - 2

A Tribute to Paul Greengard, Volume 90, the latest release in the Advances in Pharmacology series presents a variety of chapters from the best authors in the field, with this rel… Read more

Purchase options

BLOOM INTO SPRING SAVINGS

Save up to 25% on books and eBooks!

Shop now

Institutional subscription on ScienceDirect

Request a sales quote

A Tribute to Paul Greengard, Volume 90, the latest release in the Advances in Pharmacology series presents a variety of chapters from the best authors in the field, with this release presenting a tribute to Paul Greengard.

Cover image
Title page
Table of Contents
Copyright
Contributors
Preface_ A Tribute to Paul Greengard (1925–2019)
Chapter One: Paul Greengard: A persistent desire to comprehend the brain, and also to fix it
Abstract
1: Introduction
2: No to atomic research and weapons development
3: Paul's first immersion into the world of drug development
4: A brain region highly involved with diseases and disorders
5: A Rosetta Stone, a knockout mouse and a Nobel medal
6: A fascination for Alzheimer's disease
7: Forty years of knowledge stamped by an FDA approval
8: Ramping up novel therapeutic targets and pathways identification
9: 85 Years old and starting an organic chemistry extension to his lab
10: Conclusion
Chapter Two: Giving names to the actors of synaptic transmission: The long journey from synaptic vesicles to neural plasticity
Abstract
1: Introduction
2: The follow-up research directions
3: Conclusion
Chapter Three: cAMP-regulated phosphoproteins DARPP-32, ARPP16/19, and RCS modulate striatal signal transduction through protein kinases and phosphatases
Abstract
1: Introduction
2: Dopamine signaling in the basal ganglia: A brief overview
3: Identification and characterization of brain region-specific phosphoproteins
4: PKA phosphorylates DARPP-32 and inhibits PP1 in striatal neurons
5: RCS function is mediated through PKA phosphorylation
6: The ARPP-16/19 family of phosphoproteins modulates PP2A activity in a cAMP-dependent manner
7: Conclusions
Chapter Four: DARPP-32 40 years later
Abstract
1: Introduction
2: The discovery of DARPP-32
3: Regulation of DARPP-32 by phosphorylation of Thr34
4: Regulation of DARPP-32 by phosphorylation of multiple residues
5: Computational modeling of DARPP-32 phosphorylation and activity
6: Role of DARPP-32 in the physiology of the basal ganglia
7: DARPP-32 in pathological conditions
8: Conclusion
Chapter Five: Effects of nicotine on DARPP-32 and CaMKII signaling relevant to addiction
Abstract
1: Introduction
2: Nicotine addiction
3: DARPP-32
4: CaMKII
5: Conclusion
Chapter Six: Modulation of dendritic spines by protein phosphatase-1
Abstract
1: Introduction
2: Expression and targeting of PP-1 in dendritic spines
3: Regulation of protein phosphatase-1 by neurabin and spinophilin
4: Protein phosphatase-1 and neurodegenerative disorders
5: Protein phosphatase-1 and neuropsychiatric disorders
6: Conclusion
Chapter Seven: Deciphering cell-type specific signal transduction in the brain: Challenges and promises
Abstract
1: Introduction
2: Psychiatric and neurodegenerative diseases: A cell-specific perspective
3: Cell-type specific identification of pathological pathways: Current advances and remaining challenges
4: Gaining functional understanding of the cell from systems-level approaches
5: Cell-specific and network approaches in drug development and repurposing
6: Future outlook
7: Conclusion
Chapter Eight: Drug-activated cells: From immediate early genes to neuronal ensembles in addiction
Abstract
1: Introduction
2: Immediate early genes to visualize drug-activated cells: toward neuronal ensembles
3: Beyond correlation: Causal role of activated cells in controlling behavior
4: Cellular and molecular characteristics of neuronal ensembles
5: Conclusion
Chapter Nine: NAPE-specific phospholipase D regulates LRRK2 association with neuronal membranes
Abstract
1: Introduction
2: Materials and methods
3: Results
4: Discussion
Acknowledgments
Chapter Ten: Amyloidogenic and anti-amyloidogenic properties of presenilin 1
Abstract
1: Introduction
2: Alzheimer's disease
3: How does PS1 produce Abeta species?
4: Role of PS1 in neurodegeneration
5: Role of PS1 in autophagy
6: Role of PS1 in regulation of APP-C99 levels
7: Role of PS1 in microglial degradation of Abeta oligomers
8: Conclusion
Chapter Eleven: A review of the pharmacology and clinical profile of lumateperone for the treatment of schizophrenia
Abstract
1: Introduction
2: Paul Greengard and the founding of Intra-Cellular Therapies Inc (ITCI)
3: Introduction to lumateperone for the treatment of schizophrenia
4: Pharmacology of lumateperone
5: Efficacy of lumateperone for the treatment of schizophrenia
6: Efficacy summary
7: Safety profile of lumateperone
8: Conclusion
Chapter Twelve: Uniting homeostatic plasticity and exosome biology: A revision of the conceptual framework for drug discovery in neurodegenerative diseases?
Abstract
1: Introduction
2: Challenges in NDD platforms and animal models for drug discovery
3: Systematic analyses of PubMed data reveal links between homeostatic plasticity, EVs and NDDs
4: Importance of HSP in NDD: Background and emerging evidence
5: Revised conceptual framework for drug discovery research in NDDs: Part 1
6: Do EVs and miRNAs play a role in homeostatic plasticity and NDDs?
7: Revised conceptual framework for drug discovery research in NDDs: Part 2
8: Testing, validating, and building out the revised conceptual framework
9: Conclusion

Life Sciences

Physical Sciences & Engineering

Social Sciences & Humanities

Health

A Tribute to Paul Greengard (1925-2019)

Purchase options

BLOOM INTO SPRING SAVINGS

Institutional subscription on ScienceDirect

Stevin H. Zorn

Related books